Experienced in Primary Immunodeficiency (PID)

Dr. Rajneesh D. Nath

Hematology Oncology | Hematology | Oncology
Banner Cancer Center Specialists LLC
2946 E Banner Gateway Dr, 
Gilbert, AZ 
Accepting New Patients
Offers Telehealth
33 Years of Experience
Experienced in Primary Immunodeficiency (PID)
Banner Cancer Center Specialists LLC
2946 E Banner Gateway Dr, 
Gilbert, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajneesh Nath is a Hematologist Oncology specialist and a Hematologist in Gilbert, Arizona. Dr. Nath has been practicing medicine for over 33 years and is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Nath is currently accepting new patients.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Banner Gateway Medical Center
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Fallon

Accepted plan types not found. Please verify directly with the provider.

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

BANNER CANCER CENTER SPECIALISTS LLC
2946 E Banner Gateway Dr, Gilbert, AZ 85234
Other Locations
BANNER CANCER CENTER SPECIALISTS LLC
1900 N Higley Rd, Gilbert, AZ 85234

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 16, 2021
Intervention Type: Drug
Study Drugs: Rigosertib, Azacitidine
Study Phase: Phase 1/Phase 2
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

36 Total Publications

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 13, 2025
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Maqbool A. Halepota
Oncology | Hematology
Advanced in Primary Immunodeficiency (PID)
Dr. Maqbool A. Halepota
Oncology | Hematology

Palo Verde Hematology Oncology Ltd

9250 W Thomas Rd, Suite 150, 
Phoenix, AZ 
 (31.5 miles away)
623-478-8091
Languages Spoken:
English, Sindhi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Maqbool Halepota is an Oncologist and a Hematologist in Phoenix, Arizona. Dr. Halepota is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Thrombocytopenia, Familial Prostate Cancer, and Bone Marrow Aspiration. Dr. Halepota is currently accepting new patients.

Experienced in Primary Immunodeficiency (PID)
Dr. Adrienne D. Briggs
Hematology Oncology | Hematology | Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. Adrienne D. Briggs
Hematology Oncology | Hematology | Oncology

Honorhealth

10460 N 92nd St, Suite 300, 
Scottsdale, AZ 
 (16.4 miles away)
480-323-1587
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adrienne Briggs is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Briggs is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Briggs is currently accepting new patients.

Experienced in Primary Immunodeficiency (PID)
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
7200 W Bell Rd Bldg A, 
Glendale, AZ 
 (33.2 miles away)
623-487-4822
Languages Spoken:
English
See accepted insurances

Sharon Ondreyco is a Hematologist Oncology specialist and a Hematologist in Glendale, Arizona. Dr. Ondreyco is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Chronic Lymphocytic Leukemia (CLL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nath's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile